Cargando…

Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir

Lenacapavir (LEN) is a long-acting, highly potent HIV-1 capsid (CA) inhibitor. The evolution of viral variants under the genetic pressure of LEN identified Q67H, N74D, and Q67H/N74D CA substitutions as the main resistance associated mutations (RAMs). Here, we determined high-resolution structures of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bester, Stephanie M., Adu-Ampratwum, Daniel, Annamalai, Arun S., Wei, Guochao, Briganti, Lorenzo, Murphy, Bridget C., Haney, Reed, Fuchs, James R., Kvaratskhelia, Mamuka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600929/ https://www.ncbi.nlm.nih.gov/pubmed/36190128 http://dx.doi.org/10.1128/mbio.01804-22

Ejemplares similares

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir
por: Troyano-Hernáez, Paloma, et al.
Publicado: (2022)

Prion-like low complexity regions enable avid virus-host interactions during HIV-1 infection
por: Wei, Guochao, et al.
Publicado: (2022)

Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022)

Identification and Optimization of a Novel HIV-1 Integrase Inhibitor
por: Adu-Ampratwum, Daniel, et al.
Publicado: (2022)

Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)

Critical mechanistic features of HIV-1 viral capsid assembly
por: Gupta, Manish, et al.
Publicado: (2023)

1542. Impact of Subcutaneous Administration Sites on the Clinical Pharmacokinetics of Lenacapavir, a Long-Acting HIV Capsid Inhibitor: Does Body Site Matter?
por: Lat, Allen K, et al.
Publicado: (2023)

Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2023)

Lenacapavir with Fostemsavir in a Multidrug-Resistant HIV-Infected Hemodialysis Patient
por: Bigirimana, Ferdinand, et al.
Publicado: (2023)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Virus specificity and nucleoporin requirements for MX2 activity are affected by GTPase function and capsid-CypA interactions
por: Layish, Bailey, et al.
Publicado: (2023)

Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations
por: Cilento, Maria E., et al.
Publicado: (2022)

Sec24C is an HIV-1 host dependency factor crucial for virus replication
por: Rebensburg, Stephanie V., et al.
Publicado: (2021)

Multimodal Functionalities of HIV-1 Integrase
por: Engelman, Alan N., et al.
Publicado: (2022)

Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV
por: Swanstrom, Adrienne E., et al.
Publicado: (2023)

The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function
por: Singer, Matthew R., et al.
Publicado: (2023)

73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks
por: VanderVeen, Laurie, et al.
Publicado: (2021)

GS-CA1 and lenacapavir stabilize the HIV-1 core and modulate the core interaction with cellular factors
por: Selyutina, Anastasia, et al.
Publicado: (2021)

Thermodynamic instability of viral proteins is a pathogen-associated molecular pattern targeted by human defensins
por: Kudryashova, Elena, et al.
Publicado: (2016)

HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules
por: Saito, Akatsuki, et al.
Publicado: (2021)

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence
por: Zhao, Xue Zhi, et al.
Publicado: (2018)

Structural, Mechanistic, and Antigenic Characterization of the Human Astrovirus Capsid
por: York, Royce L., et al.
Publicado: (2016)

Long-acting lenacapavir acts as an effective preexposure prophylaxis in a rectal SHIV challenge macaque model
por: Bekerman, Elena, et al.
Publicado: (2023)

1581. Weight and Metabolic Changes with Long-Acting Lenacapavir in a Combination Regimen in Treatment-Naïve People with HIV-1 at Week 80
por: Kumar, Princy N, et al.
Publicado: (2023)

1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022)

1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023)

Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2
por: Kane, Melissa, et al.
Publicado: (2018)

Smectic viral capsids and the aneurysm instability
por: Dharmavaram, S, et al.
Publicado: (2018)

HIV-1 capsid is the key orchestrator of early viral replication
por: Zila, Vojtech, et al.
Publicado: (2021)

FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75
por: Kessl, Jacques J., et al.
Publicado: (2011)

The Prevalence of Malocclusion and Periodontal Diseases and Their Correlation in Samegrelo Region, Georgia
por: Kvaratskhelia, Sopiko, et al.
Publicado: (2022)

Identification of host proteins associated with HIV-1 preintegration complexes isolated from infected CD4(+ )cells
por: Raghavendra, Nidhanapati K, et al.
Publicado: (2010)

HIV-1 Integrase-DNA Recognition Mechanisms
por: Kessl, Jacques J., et al.
Publicado: (2009)

The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1
por: Saito, Akatsuki, et al.
Publicado: (2020)

Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators
por: Zhang, Xujie, et al.
Publicado: (2022)

Molecular mechanisms of retroviral integration site selection
por: Kvaratskhelia, Mamuka, et al.
Publicado: (2014)

Permeability of the HIV-1 capsid to metabolites modulates viral DNA synthesis
por: Xu, Chaoyi, et al.
Publicado: (2020)

Viral genome structures are optimal for capsid assembly
por: Perlmutter, Jason D, et al.
Publicado: (2013)

The viral capsid as novel nanomaterials for drug delivery
por: Aljabali, Alaa AA, et al.
Publicado: (2021)

Human T-lymphotropic virus type 1 p30 interacts with REGγ and ATM (Ataxia Telangiectasia Mutated) to promote cell survival
por: Anupam, Rajaneesh, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ckvh9a1dp1d63ul6d2eg87m6u1